Rigel Pharmaceuticals, Inc.
RIGLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Rigel Pharmaceuticals, Inc. focuses on Biotechnology services and products. Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The $552.5M market capitalization puts RIGL squarely in small-cap range for its industry. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Market Cap
$552.5M
Beta
1.20
P/E (TTM)
1.55
P/E (Fwd)
6.52
EPS (TTM)
$19.29
EPS (Fwd)
$4.58
ROE
174.1%
ROA
22.9%
Cash
$146.7M
Total Debt
$45.7M
Free CF
$78.6M
52W Change
46.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $146.7M in cash comfortably exceeding the $45.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $78.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 174.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 22.9% further supports the picture of efficient asset utilization. Revenue has grown from $120.2M (2022) to $294.3M (2025), reflecting a 145% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RIGL.